Gateway Biotechnology, Inc.
Olivette, MO
- UEI
- XDDXGL6JRRD9
- CAGE
- 6HBC3
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1154 N Warson Rd, Olivette, MO 63132, USA
- Website
- gtwbio.com
- Founded
- 2011
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $650,000 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | $1,299,999 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Defense Health Agency | $650,000 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Medical research and development contract DHA sbir PH II, proposal no. H2S-0048, titled: "GW-TT2, a new drug product… | Defense Health Agency | $1,949,999 |
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Gateway Biotechnology Inc. is a for-profit, minority-owned small business that provides medical research and development services to federal agencies. According to SAM.gov, Gateway is self-certified as a small disadvantaged business and is registered to receive federal contracts and grants.
Through prime contract awards, Gateway has provided medical countermeasures and quality of life therapy research and development services to the Defense Health Agency. This includes a $1.3 million firm fixed price contract to conduct Phase II of an SBIR program proposal titled "GW-TT2, A New Drug Product for Tinnitus." The research will be performed at Gateway's facilities in Ohio over a 32-month period ending in 2026. The contract has a total small business set aside designation to support innovation by small businesses.
Through prime and subcontract grants, Gateway has conducted research on therapies and diagnostic tools related to hearing loss and tinnitus. This includes a $1.6 million National Institute on Aging grant to develop a clinical diagnostic tool for age-related cochlear synaptopathy, a key pathology underlying age-related hearing loss. Gateway has also received a $4.6 million National Institute on Deafness and Other Communication Disorders grant to research targeting multiple signaling pathways for tinnitus prevention and treatment. As a subcontractor, Gateway is contributing to research on using the drug zonisamide to prevent noise-induced hearing loss in surgical and military contexts, under prime awards to Washington University and partners.
SBA capabilities narrative
Drug Research and Development
Quick answers
Is Gateway Biotechnology, Inc. registered in SAM.gov?
Yes. Gateway Biotechnology, Inc.'s SAM.gov registration is active through November 6, 2026.
How much has Gateway Biotechnology, Inc. received in federal contracts?
Federal contracts obligated $1,949,999 to Gateway Biotechnology, Inc. in fiscal years 2023 through 2027.
What is Gateway Biotechnology, Inc.'s most recent federal award?
Gateway Biotechnology, Inc.'s most recent federal contract award is Medical research and development contract DHA sbir PH II, proposal no. H2S-0048, titled: "GW-TT2, a new drug product… (HT942523C0071), from Defense Health Agency, on September 18, 2023.
On GovTribe
See Gateway Biotechnology, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors